<scp>PD‐L1</scp> inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence

Litang Huang, S. Chen, Hongxing Liu, Lu Meng, Chengxing Liu, Xiaoting Wu, Yingying Wang, Shilan Luo, Hongbin Tu, Chunlei Wang, Ming Zhang, Xiaomei GongCancer 2024 · DOI

TL;DR

Combining whole-brain radiotherapy (WBRT) with PD-L1 inhibitors significantly improves survival outcomes for patients with small cell lung cancer brain metastases (SCLC-BMs) compared to WBRT alone. Notably, administering WBRT before immunotherapy appears to yield even better results, suggesting a potentially optimized treatment sequence.

What Problem Does This Paper Address?

Small cell lung cancer (SCLC) is an aggressive form of lung cancer with a high propensity to spread to the brain, forming brain metastases (BMs). These BMs significantly worsen patient prognosis, with a median survival of only about 3 months for untreated SCLC-BMs. Whole-brain radiotherapy (WBRT) has been the standard treatment for SCLC-BMs, offering some improvement in survival. More recently, immune checkpoint inhibitors (ICIs), specifically PD-L1 inhibitors, have shown promise in treating various cancers, including SCLC. However, the optimal strategy for combining WBRT with ICIs in SCLC-BMs patients, and whether this combination offers a survival advantage over WBRT alone, remained unclear. This study aimed to address this gap by evaluating the real-world effectiveness of this combined approach.

Methods

This study employed a retrospective design, analyzing medical records of 109 patients diagnosed with SCLC-BMs between January 1, 2017, and June 1, 2022, across two centers. Patients were divided into two groups: those who received WBRT alone (n=60) and those who received WBRT combined with PD-L1 inhibitors (WBRT-ICI) (n=49). The primary endpoints analyzed were median overall survival (mOS), median progression-free survival (mPFS), and intracranial progression-free survival (iPFS). Statistical analyses included Fisher's exact test, chi-squared test, and Kaplan-Meier survival analysis with log-rank tests to compare outcomes between the groups. Cox proportional hazards regression was used to assess the relationship between various factors and mOS.

Datasets

The study utilized retrospective clinical data from 109 patients with SCLC-BMs. No new datasets were introduced or made publicly available.

Key Insights and Ideas

  • Synergy of WBRT and ICIs: The combination of WBRT and PD-L1 inhibitors is not just additive but appears to be synergistic, leading to significantly better survival outcomes than WBRT alone. This suggests that targeting both the tumor microenvironment with radiation and the immune system with ICIs is a powerful strategy.
  • Timing Matters: The sequence of treatment administration is crucial. Administering WBRT before ICI treatment was associated with a significantly longer overall survival compared to administering ICI first and then WBRT. This hints at a potential "priming" effect of radiation on the immune system that enhances ICI efficacy.
  • Biomarker Potential: Exploratory subgroup analyses suggested that certain baseline markers, like a low platelet-to-lymphocyte ratio (PLR ≤300) and a high lymphocyte-to-monocyte ratio (LMR ≥3), might predict a better response to the WBRT-ICI combination. This opens avenues for personalized treatment selection.
  • Tumor Response: The WBRT-ICI group demonstrated superior objective tumor response rates, both for brain metastases and extracranial disease, further supporting the efficacy of the combined approach.

Key Results

  • Improved Survival: The WBRT-ICI cohort showed significantly longer mOS (29.3 months vs. 20.4 months, p=0.021), mPFS (15.1 months vs. 7.9 months, p<0.001), and iPFS (16.5 months vs. 8.3 months, p<0.001) compared to the WBRT alone group.
  • Better Response Rates: The WBRT-ICI group had a higher response rate for both brain metastases (p=0.035) and extracranial diseases (p<0.001).
  • Timing Advantage: Patients receiving WBRT before ICI had a significantly better OS (34.8 months) compared to those receiving WBRT after ICI (23.3 months, p=0.020).

Limitations and Future Work

The authors acknowledge several limitations, including the retrospective nature of the study, a relatively small sample size, and potential selection bias. The quality of medical records and clinical assessments was also limited, leading to insufficient data on treatment-related adverse effects.

Future work should focus on validating these findings in larger, prospective clinical trials. Specifically, further investigation into the optimal timing of WBRT and ICI administration is warranted, as is the exploration of potential predictive biomarkers like PLR and LMR to personalize treatment strategies for SCLC-BMs patients. The study also highlights the need for more research into combination strategies for SCLC-BMs, especially for patients with oligometastases.

Summary updated

Abstract

Our results indicated that WBRT combined with immunotherapy improved survival in SCLC-BMs patients compared to WBRT monotherapy. Administering WBRT prior to ICI treatment is associated with improved survival outcomes compared to WBRT following ICI treatment, for patients with SCLC-BMs. These findings highlight the significance of conducting further prospective researches on combination strategies of intracranial radiotherapy and ICI in SCLC-BMs patients.
BibTeX
@inproceedings{huang2024scp,
  author = {Litang Huang and S. Chen and Hongxing Liu and Lu Meng and Chengxing Liu and Xiaoting Wu and Yingying Wang and Shilan Luo and Hongbin Tu and Chunlei Wang and Ming Zhang and Xiaomei Gong},
  title = {{<scp>PD‐L1</scp> inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence}},
  booktitle = {Cancer},
  year = {2024},
  doi = {10.1002/cam4.7125},
}
Figure